Valiant Laboratories Limited

Valiant Laboratories Closes Trading Window From Oct 1 for Q2 FY27 Results

Valiant Laboratories Limited will close its trading window starting October 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter and half year ended September 30, 2026, in compliance with SEBI regulations.

Valiant Laboratories Ltd. successfully conducts 5th AGM, approves financial statements and director re-appointments

Valiant Laboratories Limited held its 5th AGM on September 28, 2026. Key resolutions approved included the FY26 financial statements, re-appointment of directors, and related party transactions. Remuneration adjustments for key personnel were also approved.

Valiant Labs Holds 5th AGM on Sep 28, 2026, Discusses FY26 Performance

Valiant Laboratories Limited held its 5th AGM on September 28, 2026. The meeting focused on FY26 financial statements and re-appointments, including Mr. Santosh Vora as MD. The company highlighted improved performance, a debt-free status, and subsidiary operations. Future plans include export growth and operational efficiencies.

Valiant Laboratories to acquire 1.01% stake in AMPYR Renewable Energy for up to ₹70 Lakh

Valiant Laboratories will invest up to ₹70 Lakhs to acquire a stake in AMPYR Renewable Energy Resources Twelve A Private Limited. The acquisition aims to secure solar power for its Tarapur plant under a group captive arrangement. The company will hold up to 1.01% equity and 3.60% preference shares.

Valiant Labs Ltd. Concludes AGM Notice Dispatch; AGM on Sep 28, 2026

Valiant Laboratories Limited completed dispatch of its FY25-26 Annual Report and AGM notice. The 5th AGM is scheduled for September 28, 2026, at 11:30 AM IST via video conference. Remote e-voting will be open from September 25 to September 27, 2026.

Valiant Laboratories Gets BBB/Stable Rating for Bank Loans

Valiant Laboratories Limited's bank loan facilities have been rated IND BBB/Stable and IND A2 by India Ratings. The rated limits amount to ₹560 million (₹56 crore). This rating pertains to the company's debt instruments.

Valiant Labs to hold 5th AGM on Sep 28, 2026, dispatches Annual Report

Valiant Laboratories Limited will conduct its 5th Annual General Meeting on September 28, 2026, at 11:30 AM IST via Video Conference. The company has dispatched its Annual Report for FY 2025-26 and AGM Notice to shareholders. Shareholders can access these documents online.

Valiant Laboratories Announces 5th AGM on Sep 28, 2026, Releases Annual Report FY26

Valiant Laboratories will hold its 5th AGM on September 28, 2026. The company reported FY26 revenue of ₹217.04 crore, a 62.7% increase, and returned to profitability with PAT of ₹5.55 crore. Commercial operations began at subsidiary VASPL in November 2025. A rights issue in August 2025 raised ₹81.47 crore, leading to a debt-free status.

Valiant Laboratories Announces 5th AGM on Sep 28, 2026, via VC/OAVM

Valiant Laboratories will hold its 5th Annual General Meeting on September 28, 2026, at 11:30 AM IST via video conference. The AGM notice and FY25-26 Annual Report will be sent electronically. Members can participate and vote remotely or during the meeting.

Valiant Laboratories Publishes Q1 FY27 Financial Results

Valiant Laboratories Limited published its audited standalone and consolidated financial results for Q1 FY27, ended June 30, 2026. Standalone and consolidated total income from operations was ₹74.27 crore, with net profit after tax at ₹9.48 crore. The results were approved by the Board on August 10, 2026.

Valiant Laboratories: Monitoring Agency Report for Q1 FY27 Confirms Proper Fund Utilization

Valiant Laboratories' Monitoring Agency Report for the quarter ended June 30, 2026, confirms appropriate utilization of funds from its Rights Issue (₹8,146.88 Lakhs). No deviations from the stated objects were observed. The report was reviewed by the Audit Committee and Board on August 10, 2026.

Valiant Labs Board Approves MD Re-appointment, Office Shift, and ₹60 Cr Investment

Valiant Laboratories Limited's Board approved re-appointments for MD Santosh Vora and Independent Director Sonal Vira. The company will shift its registered office and open a new corporate office. An investment of up to ₹60 Crore in subsidiary VASPL was also approved. Re-appointments are subject to member approval.

Valiant Labs Board Approves Director Re-appointments, Office Shift, and ₹60 Cr Investment

Valiant Laboratories approved re-appointments of MD Mr. Santosh Vora and Independent Director Mrs. Sonal Vira. The registered office will shift to Palghar, and a new corporate office will open in Vikhroli. The company will also invest up to ₹60 Crore in its subsidiary, VASPL.

Valiant Labs Approves Director Re-appointments and ₹60 Cr Investment in Subsidiary

Valiant Laboratories Limited's Board approved re-appointments of Mr. Santosh Vora as MD and Mrs. Sonal Vira as Independent Director. The company will also invest up to ₹60 Crore in its subsidiary, VASPL. The registered office will be shifted, and a new corporate office opened.

Valiant Labs Approves MD Re-appointment, Director Continuation & ₹60 Crore Investment

Valiant Laboratories Limited's Board approved re-appointments for MD Mr. Santosh Vora (effective Feb 06, 2027) and Independent Director Mrs. Sonal Vira (effective Feb 16, 2027). It also approved the continuation of Mr. Shantilal Vora's directorship (effective Nov 05, 2027). The company will invest up to ₹60 Crore in its subsidiary VASPL.

Valiant Laboratories Q1FY27 Consolidated Profit Surges to ₹2,110 Lakhs

Valiant Laboratories reported its Q1 FY27 results. Consolidated net profit surged to ₹2,110.30 lakhs from ₹182.09 lakhs year-on-year. Standalone net profit was ₹947.88 lakhs, up from ₹181.56 lakhs. Revenue from operations also saw significant growth on both consolidated and standalone bases.

Valiant Laboratories Limited: Certificate under SEBI (Depositories and Participants) Regulations, 2018

Valiant Laboratories Limited received a confirmation certificate for Q1 FY27 under SEBI (Depositories and Participants) Regulations, 2018. The RTA confirmed the regulation is not applicable as all securities are in dematerialized form, with no requests for dematerialization or cancellation received during the quarter ended June 30, 2026.

Valiant Labs Clarifies Financial Results, Resolves Segment Disclosure Query

Valiant Laboratories Limited clarified its single-segment operations in response to an NSE query. The company will provide segment disclosures from the next quarter. It also addressed a missing balancing figure note in its audited financial results for the quarter and year ended March 31, 2026, with revised auditor reports now issued.

Valiant Labs receives GST order: ₹36 Lakhs demand, ₹18 Lakhs penalty confirmed

Valiant Laboratories Limited received an order confirming a GST demand of ₹18 Lakhs and a penalty of ₹18 Lakhs. The order relates to corporate guarantee and is part of a larger ₹36 Lakhs demand. Allegations regarding IPO expenses and turnover mismatch were dropped. The company is evaluating an appeal.

Valiant Organics to acquire 34.26% stake in Valiant Laboratories via off-market deal

Valiant Organics Limited will acquire 1,86,07,531 equity shares, representing 34.26% of Valiant Laboratories Limited, from Dhanvallabh Ventures LLP. This off-market transaction is part of VOL's restructuring exercise. The acquisition price will not exceed 25% of the 60-day VWAP of ₹62.71.

Valiant Labs: Promoter Entity to Transfer 34.26% Stake to Valiant Organics

Valiant Laboratories Limited announced an inter-se transfer of 1,86,07,531 equity shares (34.26%) from Dhanvallabh Ventures LLP to Valiant Organics Limited. This off-market transaction is part of a restructuring exercise. The shares will be acquired after 4 working days at a price not exceeding ₹62.71, plus 25%.

Valiant Laboratories to Explore Restructuring Options for Synergies

Valiant Laboratories Limited's Board has approved exploring potential restructuring options among the company and its group entities to achieve operational, organizational, and strategic synergies. The evaluation may involve amalgamation, merger, or demerger, aiming to unlock shareholder value and enhance business focus.

Valiant Laboratories Publishes Audited Financial Results for FY26

Valiant Laboratories published its audited financial results for the quarter and year ended March 31, 2026. Total income for the year was ₹5,842.39 crore, with a net profit of ₹363.28 crore. For the quarter, income was ₹2,199.37 crore and net profit was ₹323.83 crore. Basic EPS for the year was ₹0.74.

Valiant Labs Monitoring Agency Report for Q4FY26 Shows No Deviation in Fund Utilization

Valiant Laboratories Limited's Monitoring Agency Report for Q4FY26 confirms no deviation in the utilization of ₹814.69 crore raised via Rights Issue. Funds were used for promoter loan adjustments, promoter loan repayment, capex, and general corporate purposes. The Audit Committee and Board reviewed the report on May 14, 2026.

Valiant Labs Posts Q4 FY26 Audited Results, Reports Profit Growth

Valiant Laboratories Limited announced its audited Q4 FY26 results. Standalone profit after tax was ₹353.28 lakhs for the quarter and ₹554.82 lakhs for the year. Consolidated net profit after tax was ₹175.87 lakhs for the quarter, with a net loss of ₹326.79 lakhs for the year. The board meeting was held on May 14, 2026.

Valiant Laboratories Appoints Internal and Cost Auditors for FY27

Valiant Laboratories Limited's Board of Directors has appointed Rajesh Chheda & Co. as Internal Auditors and Ketki D Visariya & Co. as Cost Auditors for FY 2026-27. Both appointments are effective from May 14, 2026.

Valiant Labs Q4 FY26 Standalone Profit ₹353 Cr, Consolidated Profit ₹176 Cr

Valiant Laboratories reported audited standalone results for Q4 FY26 with revenue of ₹6,530 lakh and profit of ₹353 lakh. Consolidated revenue was ₹9,198 lakh with profit of ₹176 lakh. Full-year standalone revenue reached ₹21,704 lakh, and consolidated revenue was ₹23,747 lakh.

Valiant Laboratories Limited: QC Manager Mr. Bhanudas D. Patil Resigns

Mr. Bhanudas D. Patil, Q.C. Manager and Senior Management Personnel at Valiant Laboratories Limited, has resigned. His resignation is effective from the closure of business hours on April 22, 2026, due to personal commitments. The company has formally notified the stock exchanges.

Valiant Laboratories: Reg 74(5) Certificate for Q4FY26 - No Dematerialization Requests

Valiant Laboratories Limited received a certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The RTA confirmed the regulation's non-applicability as all securities are in dematerialized form, with no dematerialization requests received.

Valiant Laboratories: Trading Window Closed from April 1, 2026 for Q4FY26 Results

Valiant Laboratories Limited will close its trading window from April 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter and year ended March 31, 2026, as per SEBI regulations.

Valiant Labs Publishes Q3 FY26 Financial Results in Newspapers

Valiant Laboratories Limited published its Q3 FY26 financial results on February 13, 2026. Standalone results show Total Income of ₹15,386.12 lakh and Net Profit of ₹201.54 lakh. Consolidated results reported Total Income of ₹14,763.49 lakh and Net Loss of ₹(503.52) lakh for the quarter ended December 31, 2025.

Valiant Labs: Rights Issue Funds Utilized as Per Plan for Q3FY26

Valiant Laboratories Limited's Monitoring Agency Report for Q3FY26 confirms no deviation in the utilization of funds from its Rights Issue. Proceeds of ₹8,146.88 Lakhs were used for promoter loan adjustments, capex, and general corporate purposes. A total of ₹8,055.34 Lakhs has been utilized, with ₹91.54 Lakhs remaining.

Valiant Labs Approves Audited Q3 FY26 Standalone & Consolidated Results

Valiant Laboratories Limited's Board approved audited standalone and consolidated financial results for Q3 FY26. The results for the quarter and nine months ended December 31, 2025, were approved on February 11, 2026.

Valiant Laboratories posts Q3 FY26 results: Standalone Profit at ₹3.30 Crore, Consolidated Loss at ₹7.06 Crore

Valiant Laboratories reported standalone net profit of ₹3.30 crore for Q3 FY26, down from ₹16.00 crore year-on-year. Consolidated net loss for the quarter was ₹7.06 crore. The company's Board of Directors approved the audited financial results on February 11, 2026.

Valiant Labs Clarifies Segment Disclosure for Q2 FY26 Results

Valiant Laboratories Limited clarified its Q2 FY26 financial results, stating it operates as a single business segment as per Ind AS 108. Segment disclosure was omitted as there are no separate reportable segments. This will be disclosed from the next quarter onwards.

Valiant Labs receives ₹12.53 Cr GST demand notice for IPO expenses, turnover mismatch

Valiant Laboratories Limited received a Show-Cause Notice from CGST & Central Excise demanding ₹12.53 Crores. This includes ₹2.85 Cr for ineligible ITC on IPO expenses, ₹9.31 Cr for turnover mismatch, and ₹36 Lakhs for GST on a corporate guarantee. Applicable interest and penalties are also proposed.

Valiant Laboratories Ltd: Certificate under SEBI Reg. 74(5) for Q3 FY26

Valiant Laboratories Limited received a certificate under SEBI Regulation 74(5) for the quarter ended December 31, 2025. The company's RTA confirmed the regulation's non-applicability as all securities are in dematerialized form, with no requests for dematerialization or cancellation received.

Valiant Labs Receives GST Order Demanding ₹62.97 Lakhs, Including Penalty

Valiant Laboratories Limited received a GST order demanding ₹57.25 Lakhs for wrongly availed Input Tax Credit on capital goods for FY 2021-22. The company faces a total demand of ₹62.97 Lakhs, including a penalty of ₹5.72 Lakhs. The company is evaluating options to appeal the order.

Valiant Laboratories Closes Trading Window from Jan 1, 2026, for Q3 FY26 Results

Valiant Laboratories Limited will close its trading window from January 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter and nine-months ended December 31, 2025. This is in compliance with SEBI regulations.

Valiant Laboratories Reports Strong Profitability Turnaround for Q2 and H1 FY25

Valiant Laboratories announced its Q2 and H1 FY25 financial results, showing a significant turnaround from losses to profits. Net income reached ₹0.17 crore for Q2 and ₹1.98 crore for H1.

Valiant Laboratories Board Comments on SEBI Fine for Delayed Rights Issue Committee Intimation

Valiant Laboratories' Board clarified that a ₹11,800 SEBI fine for delayed Rights Issue Committee meeting intimation was due to practical challenges, not deliberate non-compliance, and the fine has been paid.

Valiant Laboratories: Q2 FY26 Rights Issue funds utilization compliant, no deviations found

Valiant Laboratories' Monitoring Agency Report for Q2 FY26 confirms appropriate utilization of ₹8,146.88 Lakhs from its Rights Issue, with no deviations from stated objects.

Valiant Laboratories Reports Strong Q2 & H1 FY26 Results, Returns to Profitability

Valiant Laboratories reported robust Q2 and H1 FY26 financial results, achieving significant revenue growth and a strong return to profitability both standalone and consolidated, following board approval on November 11, 2025.

Valiant Laboratories Approves Audited Financial Results for Quarter Ended September 30, 2025

Valiant Laboratories approved audited standalone and consolidated financial results for quarter and half year ended September 30, 2025, in board meeting held on November 11, 2025.

Valiant Advanced Sciences commences operations at Gujarat facility

Valiant Advanced Sciences, a subsidiary of Valiant Laboratories, starts commercial operations at its new manufacturing facility in Saykha, Gujarat, focusing on Acetic Anhydride production.

Valiant Laboratories files Regulation 74(5) Certificate for Q2 FY26

Valiant Laboratories submitted its Regulation 74(5) certificate for Q2 FY26, confirming all securities are dematerialized and no requests for physical share processing were received.

Valiant Laboratories Receives Show Cause Notice Regarding ITC Disallowance

Valiant Laboratories: AGM Approves Director Re-appointment, CFO Designation Change, and Auditor Appointment

Valiant Laboratories announces 4th AGM via VC/OAVM on September 25, 2025

Valiant Laboratories Allots Equity Shares on Rights Basis